CA-AGENDIA
16.11.2022 15:01:35 CET | Business Wire | Press release
Agendia, Inc., a commercial-stage company focused on assessing an individual tumor’s risk of metastasis and the molecular subtyping reasons for its growth, today announced the first patient has enrolled in the LESS clinical trial, sponsored by Unicancer with the institutional support of Agendia. In an effort to improve outcomes while preserving quality of life for early breast cancer patients, the study is designed to safely discontinue adjuvant endocrine therapy after two years for tumors with a MammaPrint Ultra Low result in post-menopausal women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. The study aims to enroll 696 patients via 45 sites within the French breast cancer intergroup Unicancer (UCBG) by October 2024.
“We are excited to identify early breast cancer tumors and further investigate the ability to reduce endocrine therapy duration, in an effort to minimize significant and varying side effects, while maintaining high survival rates,” said Fabrice André, MD, PhD, Professor in the Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France and Co-coordinating Investigator of the study.
Elise Deluche, MD, Deputy Head of Department at Centre Hospitalier Universitaire de Limoges and Co-coordinating Investigator of the study, added, “Enabling personalized treatments to prevent over- and undertreatment in breast cancer care could give women freedom from intensive long-term treatment regimens that may not increase their chance of cure.”
Previous studies have shown patients with HR+/HER2- breast cancer with a MammaPrint Ultra Low result can have an excellent prognosis at 20 years with reduced endocrine therapy.
“The LESS study is an important addition to Agendia leading the field in uncovering robust insights for patients and their providers to tailor treatments unique to every tumor,” said William Audeh, MD, Chief Medical Officer at Agendia. “Through our partnership with Unicancer, we are expanding knowledge on the complexity of breast cancer and enabling further personalized treatments in cancer care.”
Agendia’s singular focus on breast cancer facilitates continued investment in global research to unravel the intricacies of precision medicine and drive personalized treatment planning for women with breast cancer. This study reinforces Agendia’s commitment to practice changing research that will aid decision-making, aimed at improving outcomes.
About Agendia
Agendia is a mission-driven, commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey.
MammaPrint® is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient’s breast cancer recurrence risk. BluePrint® is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint® and BluePrint® provide a holistic view of the biology underlying an individual patient’s breast cancer, enabling physicians to objectively select the best treatment plan.
For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.
About Unicancer
Unicancer is the only French hospital network 100% dedicated to the fight against cancer and the only national hospital federation dedicated to cancer. It brings together the 18 French Cancer Comprehensive Centres (FCCCs), private not-profit health establishments, spread over 20 hospital sites in France, as well as 2 affiliated establishments. The FCCCs take care of nearly 540,000 patients per year (in short-stay, HAD and outpatient procedures). Unicancer is also the leading academic promoter of clinical trials in oncology, on a European scale, with 109 active clinical trials promoted, 20,000 patients included, 83,000 patients registered in the ESME database. Recognised as a leader in research in France, the Unicancer network enjoys a worldwide reputation with the production of one third of French publications of international importance in oncology (source: bibliometric study/Thomson Reuters). In total, more than 700 clinical trials (inclusions or follow-ups) are promoted in 2021 by the Unicancer network, more than 16% of CLCC patients are included in clinical trials and more than half of the PHRCs devolved to FCCCs.
The 18 FCCCs and the Unicancer R&D department are ISO 9001 certified.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005249/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Miro Takes Aim at the Gap Between AI Potential and Organizational Reality19.5.2026 16:00:00 CEST | Press release
At Canvas 26, Miro establishes its AI platform as the connective layer of the modern AI ecosystem — bringing together teams, agents, and the tools they already work in to turn individual AI productivity into organization-wide transformation Miro®, the AI Innovation Workspace for teams, has announced new innovations across its AI platform, reinforcing its position as the collaboration layer where people, context, and agents from every function converge to solve hard problems, make better decisions, and build the right thing faster. Major upgrades to Miro’s agentic AI tools — including Sidekicks and Flows — alongside new Connectors, help customers close the gap between individual AI productivity and organization-wide transformation. AI is reshaping the pace of work, but often teams are not realising the benefits. In many organizations, a gap has emerged between what individuals can now do and what companies can harness. The reason? Collaboration has fractured. Teams have moved from one m
Wolters Kluwer Medi-Span Selected to Provide Personalized Medication Decision Support at The Christie NHS Foundation Trust19.5.2026 15:30:00 CEST | Press release
Roll-out at largest EU cancer center marks first Medi-Span NHS implementation Wolters Kluwer Health has implemented its industry-leading medication decision support (MDS) solution, Medi-Span®, at the world-renowned specialist oncology center, The Christie NHS Foundation Trust. “The Christie is recognized globally for its excellence and commitment to delivering exceptional patient care,” says Israel Armstrong, Vice President for Medi-Span International at Wolters Kluwer Health. “We’re proud that our first Medi-Span implementation in the NHS should be with such a prestigious institution. We look forward to more collaborations that help streamline processes further and help clinical teams make the most highly informed decisions.” The Christie is a leading expert in cancer care, research and education and is the largest single-site cancer center in Europe. The Christie treats more than 60,000 patients a year and is the first facility in the UK to be accredited as a comprehensive cancer cen
Torq Acquires Jit to Unleash the First Enterprise AI SOC Context Graph—and Rewrite the Future of SecOps19.5.2026 15:00:00 CEST | Press release
With Jit Acquisition, Torq Catapults Enterprise SOCs Into a New Realm of Detailed Contextual Investigations That Drive Precision Decision-Making Torq, the established agentic security operations leader, today announced the acquisition of Jit, the Boston-based AI Context Graph cybersecurity pioneer. This move marks a dramatic leap forward for the Torq AI SOC Platform by ensuring agentic investigations are precisely informed via organization-specific contextual data. This shift redefines agentic reasoning, moving beyond static facts such as users, devices and their relationships, to prioritize live, dynamic contextual data overlaid on top, including business drivers, and the real-time state of the enterprise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519044833/en/ Instead of acting on fragmented data or having investigations triggered by a single alert, Torq AI operates with a unified, continuously-updated, contextual
Nine in 10 Firms Fear In-House Systems Can’t Keep Pace with Executive Pay Demands19.5.2026 15:00:00 CEST | Press release
89% of senior HR, rewards, and compensation leaders say in-house technology cannot keep pace with executive compensation demands80% report increased participation in incentive schemes over the past three years66% identify reliance on multiple service providers as a key barrier to maintaining accurate and consistent data Managing executive compensation is a growing challenge for financial services firms, with nearly nine in 10 (89%) saying their in-house technology can’t keep pace with demand. New research by CSC, the leading provider of business administration and compliance solutions, shows that rising complexity, regulatory pressure, and expanding global participation place increasing strain on internal systems and teams.1 CSC surveyed 300 senior HR, rewards, and compensation leaders across Europe, Asia Pacific, and North America working in private markets, asset management, insurance, and investment banking. The report, The Future of Reward in Financial Services: Executive Compensat
Tacton Appoints Manufacturing Technology Leader Mike DiTullio to Board of Directors19.5.2026 15:00:00 CEST | Press release
Former PTC President & COO brings decades of experience serving complex manufacturers and scaling global commercial organizations as Tacton advances growth in North America and EMEA. Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex products, today announced the appointment of Mike DiTullio to its Board of Directors. DiTullio is an enterprise software executive with more than three decades of experience working with complex manufacturers. He joins at a pivotal moment in the company’s evolution as Tacton expands beyond CPQ to deliver the Buyer-Centric Smart Factory, a connected approach that unites buyer engagement, engineering, and order fulfillment into a single intelligent system. DiTullio spent 26 years at PTC, most recently as President and Chief Operating Officer, wherehe worked closely with leading manufacturers to transform how they design, sell, and deliver complex products. In that role, he led global commercial operations across s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom